{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:48:15Z","timestamp":1793659695120,"version":"4.5.1"},"reference-count":251,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171167"],"award-info":[{"award-number":["32171167"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.heliyon.2025.e41629","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:49:49Z","timestamp":1736045389000},"page":"e41629","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3060-3629","authenticated-orcid":false,"given":"Zhuangqi","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-2722","authenticated-orcid":false,"given":"Shuxin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10015","key":"10.1016\/j.heliyon.2025.e41629_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(15)00551-6","article-title":"Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013","volume":"387","author":"Zhou","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2024.102459","article-title":"Trends towards increase of Cardiovascular diseases mortality in USA: a comparison with Europe and the importance of preventive care","volume":"49","author":"Sterpetti","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"10.1016\/j.heliyon.2025.e41629_bib3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","article-title":"Trends in lipid-modifying agent use in 83 countries","volume":"328","author":"Blais","year":"2021","journal-title":"Atherosclerosis"},{"issue":"6 Pt 1","key":"10.1016\/j.heliyon.2025.e41629_bib4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.biotechadv.2015.04.001","article-title":"Lovastatin production: from molecular basis to industrial process optimization","volume":"33","author":"Mulder","year":"2015","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010466","article-title":"Statins-from fungi to pharmacy","volume":"25","author":"Sadowska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2025.e41629_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","article-title":"The pharmacology of statins","volume":"88","author":"Sirtori","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib7","first-page":"328","article-title":"HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview","volume":"22","author":"Balasubramanian","year":"2021","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/clpt.2009.197","article-title":"Transporter pharmacogenetics and statin toxicity","volume":"87","author":"Niemi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/07853890.2011.582135","article-title":"Clinical response to statins: mechanism(s) of variable activity and adverse effects","volume":"44","author":"Sirtori","year":"2012","journal-title":"Ann. Med."},{"key":"10.1016\/j.heliyon.2025.e41629_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"21","key":"10.1016\/j.heliyon.2025.e41629_bib11","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/01.HYP.37.6.1450","article-title":"HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species","volume":"37","author":"Wassmann","year":"2001","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib13","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jcmg.2011.11.012","article-title":"Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS","volume":"5","author":"Hattori","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1161\/01.RES.83.7.683","article-title":"3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins","volume":"83","author":"Essig","year":"1998","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.04.011","article-title":"Statins and cancer: current and future prospects","volume":"324","author":"Osmak","year":"2012","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1902\/jop.2016.160075","article-title":"Effects of atorvastatin on periodontitis of rats subjected to glucocorticoid-induced osteoporosis","volume":"87","author":"Sousa","year":"2016","journal-title":"J. Periodontol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib17","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jbspin.2012.07.007","article-title":"Rosuvastatin inhibits spontaneous and IL-1\u03b2-induced interleukin-6 production from human cultured osteoblastic cells","volume":"80","author":"Lazzerini","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib18","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0022034513516980","article-title":"Simvastatin inhibits LPS-induced alveolar bone loss during metabolic syndrome","volume":"93","author":"Jin","year":"2014","journal-title":"J. Dent. Res."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib19","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1210\/en.2011-0016","article-title":"Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation","volume":"152","author":"Weivoda","year":"2011","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.2001.5597","article-title":"Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts","volume":"287","author":"Ohnaka","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.nutres.2010.03.004","article-title":"Simvastatin promotes osteoblast viability and differentiation via Ras\/Smad\/Erk\/BMP-2 signaling pathway","volume":"30","author":"Chen","year":"2010","journal-title":"Nutr. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1677\/JOE-07-0532","article-title":"Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras\/Rho-mitogen-activated protein kinase pathway","volume":"196","author":"Yamashita","year":"2008","journal-title":"J. Endocrinol."},{"issue":"4 Suppl","key":"10.1016\/j.heliyon.2025.e41629_bib23","first-page":"32","article-title":"Statins, fracture risk, and bone remodeling","volume":"32","author":"Luisetto","year":"2009","journal-title":"J. Endocrinol. Invest."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI82585","article-title":"Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair","volume":"126","author":"Hu","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1600-0765.2010.01329.x","article-title":"Lactone form 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) stimulate the osteoblastic differentiation of mouse periodontal ligament cells via the ERK pathway","volume":"46","author":"Kim","year":"2011","journal-title":"J. Periodontal. Res."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1055\/s-0028-1082051","article-title":"Statin suppresses apoptosis in osteoblastic cells: role of transforming growth factor-beta-Smad3 pathway","volume":"40","author":"Kaji","year":"2008","journal-title":"Horm. Metab. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.job.2021.06.002","article-title":"Statins with potential to control periodontitis: from biological mechanisms to clinical studies","volume":"63","author":"de Carvalho","year":"2021","journal-title":"J. Oral Biosci."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib28","doi-asserted-by":"crossref","first-page":"R187","DOI":"10.1186\/ar4018","article-title":"Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis","volume":"14","author":"Kim","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib29","article-title":"Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis","volume":"8","author":"de Ara\u00fajo J\u00fanior","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-2005-870538","article-title":"Statins modulate the levels of osteoprotegerin\/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures","volume":"37","author":"Kaji","year":"2005","journal-title":"Horm. Metab. Res."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3904\/kjim.2015.244","article-title":"Atorvastatin inhibits osteoclast differentiation by suppressing NF-\u03baB and MAPK signaling during IL-1\u03b2-induced osteoclastogenesis","volume":"33","author":"Lee","year":"2018","journal-title":"Korean J Intern Med"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib32","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbrc.2004.11.097","article-title":"Mechanisms of sex steroid effects on bone","volume":"328","author":"Syed","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00774-010-0231-y","article-title":"Simvastatin induces estrogen receptor-alpha expression in bone, restores bone loss, and decreases ER\u03b1 expression and uterine wet weight in ovariectomized rats","volume":"29","author":"Li","year":"2011","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib34","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jss.2010.12.029","article-title":"Simvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors \u03b1","volume":"174","author":"Park","year":"2012","journal-title":"J. Surg. Res."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bcp.2015.09.018","article-title":"Estrogen receptor mediates simvastatin-stimulated osteogenic effects in bone marrow mesenchymal stem cells","volume":"98","author":"Chuang","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.heliyon.2025.e41629_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/bs.acc.2015.10.005","article-title":"Biochemistry of statins","volume":"73","author":"Egom","year":"2016","journal-title":"Adv. Clin. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib37","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s42255-019-0054-7","article-title":"KLF15 regulates endobiotic and xenobiotic metabolism","volume":"1","author":"Han","year":"2019","journal-title":"Nat. Metab."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12071467","article-title":"Decoding the role of CYP450 enzymes in metabolism and disease: a comprehensive review","volume":"12","author":"Hossam Abdelmonem","year":"2024","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib39","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41416-019-0722-0","article-title":"Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression","volume":"122","author":"Allain","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103349","article-title":"Pharmacogenetics of human sulfotransferases and impact of amino acid exchange on Phase II drug metabolism","volume":"27","author":"Isvoran","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/biom13040688","article-title":"The multifaceted role of glutathione S-transferases in health and disease","volume":"13","author":"Mazari","year":"2023","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28031151","article-title":"Transporter-mediated drug delivery","volume":"28","author":"Gyimesi","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2016.08.001","article-title":"Drug metabolism in the liver","volume":"21","author":"Almazroo","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.heliyon.2025.e41629_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or lipophilic statins?","volume":"8","author":"Climent","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib45","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1021\/acs.molpharmaceut.5b00474","article-title":"Statin lactonization by uridine 5'-Diphospho-glucuronosyltransferases (UGTs)","volume":"12","author":"Schirris","year":"2015","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17425255.2020.1801634","article-title":"An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins","volume":"16","author":"Hirota","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.heliyon.2025.e41629_bib47","series-title":"StatPearls","article-title":"Atorvastatin","author":"McIver","year":"2024"},{"issue":"13","key":"10.1016\/j.heliyon.2025.e41629_bib48","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.2165\/00003088-200342130-00005","article-title":"Clinical pharmacokinetics of atorvastatin","volume":"42","author":"Lennern\u00e4s","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib49","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/jpet.105.093088","article-title":"Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems","volume":"316","author":"Lau","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib50","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0090-9556(24)15086-6","article-title":"Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin","volume":"28","author":"Jacobsen","year":"2000","journal-title":"Drug Metab. Dispos."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1124\/dmd.121.000406","article-title":"Comparative hepatic and intestinal metabolism and pharmacodynamics of statins","volume":"49","author":"Filppula","year":"2021","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib52","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1124\/dmd.121.000430","article-title":"Comparative hepatic and intestinal efflux transport of statins","volume":"49","author":"Deng","year":"2021","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib53","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/j.1552-4604.1992.tb05773.x","article-title":"Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers","volume":"32","author":"Tse","year":"1992","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib54","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-200140040-00003","article-title":"Clinical pharmacokinetics of fluvastatin","volume":"40","author":"Scripture","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib55","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.clpt.2006.06.010","article-title":"SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin","volume":"80","author":"Niemi","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib56","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejps.2011.09.009","article-title":"Interaction of fluvastatin with the liver-specific Na+ -dependent taurocholate cotransporting polypeptide (NTCP)","volume":"44","author":"Greupink","year":"2011","journal-title":"Eur J Pharm Sci"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib57","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1742-7843.2009.00453.x","article-title":"Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes","volume":"105","author":"Toda","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0090-9556(25)07457-4","article-title":"Biotransformation of fluvastatin sodium in humans","volume":"21","author":"Dain","year":"1993","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib59","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/mp0499297","article-title":"Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2","volume":"1","author":"Lindahl","year":"2004","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00003088-199427020-00002","article-title":"Clinical pharmacokinetics of pravastatin","volume":"27","author":"Quion","year":"1994","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00003088-200039060-00002","article-title":"Clinical pharmacokinetics of pravastatin: mechanisms of pharmacokinetic events","volume":"39","author":"Hatanaka","year":"2000","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib62","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2125.1990.tb03626.x","article-title":"Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects","volume":"29","author":"Singhvi","year":"1990","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"52","key":"10.1016\/j.heliyon.2025.e41629_bib63","doi-asserted-by":"crossref","first-page":"37161","DOI":"10.1074\/jbc.274.52.37161","article-title":"A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters","volume":"274","author":"Hsiang","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib64","first-page":"904","volume":"16","author":"Tokui","year":"1999","journal-title":"Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharm Res"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib65","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1021\/acs.molpharmaceut.8b00138","article-title":"Relative activity factor (RAF)-Based scaling of uptake clearance mediated by organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 in human hepatocytes","volume":"15","author":"Izumi","year":"2018","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11095-006-9159-2","article-title":"Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans","volume":"24","author":"Kivist\u00f6","year":"2007","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/jpet.105.084830","article-title":"Bile salt export pump (BSEP\/ABCB11) can transport a nonbile acid substrate, pravastatin","volume":"314","author":"Hirano","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1124\/mol.105.014019","article-title":"Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin","volume":"68","author":"Hirano","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib69","doi-asserted-by":"crossref","first-page":"348","DOI":"10.2165\/00003088-199631050-00003","article-title":"Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors","volume":"31","author":"Desager","year":"1996","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib70","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/FPC.0000000000000148","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid","volume":"25","author":"Tornio","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib71","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0003-9861(91)90551-S","article-title":"Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes","volume":"290","author":"Wang","year":"1991","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0090-9556(24)15273-7","article-title":"Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver","volume":"27","author":"Jacobsen","year":"1999","journal-title":"Drug Metab. Dispos."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib73","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib74","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-017-0213-8","article-title":"Pitavastatin: a review in hypercholesterolemia","volume":"17","author":"Hoy","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib75","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.clpt.6100190","article-title":"SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers","volume":"82","author":"Ieiri","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/jpet.104.068056","article-title":"Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans","volume":"311","author":"Hirano","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib77","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/bdd.1861","article-title":"Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin","volume":"34","author":"Bi","year":"2013","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1567-5688(11)70886-8","article-title":"Pitavastatin: an overview","volume":"12","author":"Saito","year":"2011","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib80","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/0049825021000017957","article-title":"Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization","volume":"33","author":"Fujino","year":"2003","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib81","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.taap.2013.03.019","article-title":"ATP-dependent transport of statins by human and rat MRP2\/Mrp2","volume":"269","author":"Ellis","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40262-020-00978-9","article-title":"Pharmacokinetics of rosuvastatin: a systematic review of randomised controlled trials in healthy adults","volume":"60","author":"Kanukula","year":"2021","journal-title":"Clin. Pharmacokinet."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib83","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/S0149-2918(03)80336-3","article-title":"Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers","volume":"25","author":"Martin","year":"2003","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib84","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s11095-021-03109-6","article-title":"Physiologically based pharmacokinetic modeling of rosuvastatin to predict transporter-mediated drug-drug interactions","volume":"38","author":"Hanke","year":"2021","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib85","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib86","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00228-002-0508-8","article-title":"The effect of fluconazole on the pharmacokinetics of rosuvastatin","volume":"58","author":"Cooper","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib87","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib88","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/dmd.105.007534","article-title":"ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein","volume":"34","author":"Huang","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib89","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00003088-199324030-00002","article-title":"Clinical pharmacokinetics and practical applications of simvastatin","volume":"24","author":"Mauro","year":"1993","journal-title":"Clin. Pharmacokinet."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib90","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.fpc.0000230416.82349.90","article-title":"SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid","volume":"16","author":"Pasanen","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib91","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11095-007-9519-6","article-title":"Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms","volume":"25","author":"Tubic-Grozdanis","year":"2008","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib92","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0009-9236(01)25429-0","article-title":"Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin","volume":"70","author":"Mulder","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib93","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bph.15298","article-title":"Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin","volume":"178","author":"Li","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.heliyon.2025.e41629_bib94","series-title":"LIPITOR- atorvastatin calcium tablet, film coated","year":"2022"},{"key":"10.1016\/j.heliyon.2025.e41629_bib97","series-title":"LOVASTATIN tablet","article-title":"Dailymed","year":"2024"},{"key":"10.1016\/j.heliyon.2025.e41629_bib98","series-title":"PITAVASTATIN CALCIUM- pitavastatin calcium tablet, film coated","year":"2024"},{"key":"10.1016\/j.heliyon.2025.e41629_bib99","series-title":"SIMVASTATIN- simvastatin tablet, film coated","year":"2024"},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib100","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"e1","key":"10.1016\/j.heliyon.2025.e41629_bib101","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1136\/ejhpharm-2022-003333","article-title":"Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis","volume":"30","author":"Tsui","year":"2023","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib102","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1136\/annrheumdis-2019-215714","article-title":"Diagnosis of osteoporosis in statin-treated patients is dose-dependent","volume":"78","author":"Leutner","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"22","key":"10.1016\/j.heliyon.2025.e41629_bib103","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph182211902","article-title":"Association between osteoporosis and previous statin use: a nested case-control study","volume":"18","author":"Kim","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054158","article-title":"Comparative efficacy and safety of statins for osteoporosis: a study protocol for a systematic review and network meta-analysis","volume":"12","author":"Xiong","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2025.e41629_bib105","article-title":"The complex interplay of sex steroids and sex hormone-binding globulin in determining fracture risk in men","author":"Khosla","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib106","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.dmpk.2016.09.002","article-title":"A possible role for HLA-DRB1\u221704:06 in statin-related myopathy in Japanese patients","volume":"31","author":"Sai","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"issue":"25","key":"10.1016\/j.heliyon.2025.e41629_bib107","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib108","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","article-title":"Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy","volume":"79","author":"Hermann","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2025.e41629_bib109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.athplu.2024.01.001","article-title":"The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; an exploratory case-control study","volume":"55","author":"Lauritzen","year":"2024","journal-title":"Atheroscler Plus"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib110","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s11095-005-9371-5","article-title":"Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport","volume":"23","author":"Sakaeda","year":"2006","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"4\u20135","key":"10.1016\/j.heliyon.2025.e41629_bib111","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejps.2007.12.009","article-title":"Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro","volume":"33","author":"Skottheim","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.heliyon.2025.e41629_bib112","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.trsl.2016.03.015","article-title":"The role of acid-base imbalance in statin-induced myotoxicity","volume":"174","author":"Taha","year":"2016","journal-title":"Transl. Res."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib113","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.tiv.2010.06.006","article-title":"Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes","volume":"24","author":"Ellesat","year":"2010","journal-title":"Toxicol. Vitro"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib114","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expet Opin. Drug Saf."},{"issue":"20","key":"10.1016\/j.heliyon.2025.e41629_bib115","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib116","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR myopathy","volume":"5","author":"Mohassel","year":"2018","journal-title":"J. Neuromuscul. Dis."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib117","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3949\/ccjm.81a.13158","article-title":"Identifying statin-associated autoimmune necrotizing myopathy","volume":"81","author":"Albayda","year":"2014","journal-title":"Cleve. Clin. J. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib118","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11926-018-0732-6","article-title":"Immune-mediated necrotizing myopathy","volume":"20","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib119","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2014.6190","article-title":"Statins trigger mitochondrial reactive oxygen species-induced apoptosis in glycolytic skeletal muscle","volume":"24","author":"Bouitbir","year":"2016","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib120","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00204-018-2369-7","article-title":"PGC-1\u03b2 modulates statin-associated myotoxicity in mice","volume":"93","author":"Singh","year":"2019","journal-title":"Arch. Toxicol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib121","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13402","article-title":"PGC-1\u03b1 plays a pivotal role in simvastatin-induced exercise impairment in mice","volume":"228","author":"Panajatovic","year":"2020","journal-title":"Acta Physiol."},{"issue":"37","key":"10.1016\/j.heliyon.2025.e41629_bib122","doi-asserted-by":"crossref","first-page":"eade5927","DOI":"10.1126\/sciadv.ade5927","article-title":"Unraveling a mystery: why human cells require cholesterol","volume":"8","author":"Yeagle","year":"2022","journal-title":"Sci. Adv."},{"issue":"13","key":"10.1016\/j.heliyon.2025.e41629_bib123","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib124","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/10409238.2018.1458070","article-title":"Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease","volume":"53","author":"Jeong","year":"2018","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"Pt 5","key":"10.1016\/j.heliyon.2025.e41629_bib125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1242\/jcs.01660","article-title":"The Ras superfamily at a glance","volume":"118","author":"Wennerberg","year":"2005","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.heliyon.2025.e41629_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.029","article-title":"Myotoxicity of statins: mechanism of action","volume":"175","author":"du Souich","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib127","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.bcp.2009.12.007","article-title":"Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy","volume":"79","author":"Mullen","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib128","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/taap.1997.8174","article-title":"HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/taap.1997.8131","article-title":"Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro","volume":"145","author":"Flint","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.taap.2004.04.010","article-title":"Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone","volume":"200","author":"Johnson","year":"2004","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib131","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.xphs.2016.01.014","article-title":"Involvement of monocarboxylate transporter 4 expression in statin-induced cytotoxicity","volume":"105","author":"Kikutani","year":"2016","journal-title":"J Pharm Sci"},{"issue":"17","key":"10.1016\/j.heliyon.2025.e41629_bib132","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/febs.12253","article-title":"Mechanisms regulating skeletal muscle growth and atrophy","volume":"280","author":"Schiaffino","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.heliyon.2025.e41629_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2021.109024","article-title":"EphA2 inhibits SRA01\/04 cells apoptosis by suppressing autophagy via activating PI3K\/Akt\/mTOR pathway","volume":"711","author":"Han","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib134","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.bbamcr.2015.04.010","article-title":"The AKT\/mTOR signaling pathway plays a key role in statin-induced myotoxicity","volume":"1853","author":"Bonifacio","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.heliyon.2025.e41629_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114750","article-title":"mTORC2 is an important target for simvastatin-associated toxicity in C2C12 cells and mouse skeletal muscle - roles of Rap1 geranylgeranylation and mitochondrial dysfunction","volume":"192","author":"Sanvee","year":"2021","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib136","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","article-title":"Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib138","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib139","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am. J. Cardiol."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib140","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib141","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","article-title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy","volume":"47","author":"Bogsrud","year":"2013","journal-title":"Scand. Cardiovasc. J."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib142","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib143","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1139\/cjpp-2012-0118","article-title":"Coenzyme Q(10) and selenium in statin-associated myopathy treatment","volume":"91","author":"Fedacko","year":"2013","journal-title":"Can. J. Physiol. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib144","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3810\/psm.2012.11.1991","article-title":"Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins","volume":"40","author":"Deichmann","year":"2012","journal-title":"Phys Sportsmed"},{"key":"10.1016\/j.heliyon.2025.e41629_bib145","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.heliyon.2025.e41629_bib146","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.2147\/DDDT.S223153","article-title":"Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study","volume":"13","author":"Derosa","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib147","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/eurheartj\/ehr224","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1","volume":"33","author":"Bouitbir","year":"2012","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib148","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2015.08.002","article-title":"Statin-induced myopathy is associated with mitochondrial complex III inhibition","volume":"22","author":"Schirris","year":"2015","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib149","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbrc.2005.10.108","article-title":"Simvastatin induces impairment in skeletal muscle while heart is protected","volume":"338","author":"Sirvent","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib150","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1152\/physrev.2000.80.3.1215","article-title":"Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease","volume":"80","author":"Berchtold","year":"2000","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib151","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1124\/jpet.106.118331","article-title":"Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum\/mitochondria Ca2+-release system","volume":"321","author":"Liantonio","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"5\u20136","key":"10.1016\/j.heliyon.2025.e41629_bib152","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0143416002002014","article-title":"Endoplasmic reticulum, Bcl-2 and Ca2+ handling in apoptosis","volume":"32","author":"Ferrari","year":"2002","journal-title":"Cell Calcium"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib153","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0166-2236(99)01479-4","article-title":"Calpain and caspase: can you tell the difference?","volume":"23","author":"Wang","year":"2000","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib154","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0014-5793(95)00405-X","article-title":"Association of high molecular weight DNA fragmentation with apoptotic or non-apoptotic cell death induced by calcium ionophore","volume":"364","author":"Kataoka","year":"1995","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib155","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaccas.2019.12.019","article-title":"Statin-induced necrotizing autoimmune myopathy","volume":"2","author":"Gawey","year":"2020","journal-title":"JACC Case Rep"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib156","doi-asserted-by":"crossref","first-page":"543","DOI":"10.14218\/JCTH.2021.00271","article-title":"Statin-induced liver injury patterns: a clinical review","volume":"10","author":"Averbukh","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib157","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.27157","article-title":"Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network","volume":"60","author":"Russo","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib158","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1515\/aiht-2017-68-2994","article-title":"Hepatotoxicity associated with statins","volume":"68","author":"Karahalil","year":"2017","journal-title":"Arh. Hig. Rada. Toksikol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib159","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2011.07.023","article-title":"Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing","volume":"56","author":"Bj\u00f6rnsson","year":"2012","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib160","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00204-013-1034-4","article-title":"Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis","volume":"87","author":"Sinha","year":"2013","journal-title":"Arch. Toxicol."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib161","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.taap.2007.05.013","article-title":"Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity?","volume":"223","author":"Tavintharan","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib162","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00204-014-1334-3","article-title":"High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins","volume":"89","author":"Tolosa","year":"2015","journal-title":"Arch. Toxicol."},{"issue":"15","key":"10.1016\/j.heliyon.2025.e41629_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158343","article-title":"Interactive relationships between intestinal flora and bile acids","volume":"23","author":"Guo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib164","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF03260010","article-title":"Drug-induced cholestasis","volume":"2","author":"Zimmerman","year":"1987","journal-title":"Med. Toxicol."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib165","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1194\/jlr.M053124","article-title":"Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice","volume":"55","author":"Fu","year":"2014","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib166","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1499-3872(14)60009-6","article-title":"Pravastatin activates the expression of farnesoid X receptor and liver X receptor alpha in Hep3B cells","volume":"13","author":"Byun","year":"2014","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib167","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/FJC.0000000000001425","article-title":"Effects of atorvastatin on bile acid metabolism in high-fat diet-fed ApoE -\/- mice","volume":"81","author":"Li","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.heliyon.2025.e41629_bib168","doi-asserted-by":"crossref","first-page":"e3348","DOI":"10.7717\/peerj.3348","article-title":"Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice","volume":"5","author":"Li","year":"2017","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib169","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14071491","article-title":"CYP3A5\u22173 and SLCO1B1 c.521T>C polymorphisms influence the pharmacokinetics of atorvastatin and 2-hydroxy atorvastatin","volume":"14","author":"Park","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib171","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2025.e41629_bib172","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12944-015-0114-2","article-title":"ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis","volume":"14","author":"Su","year":"2015","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib173","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s43440-021-00319-y","article-title":"Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts","volume":"74","author":"Dagli-Hernandez","year":"2022","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib174","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44792-2","article-title":"Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study","volume":"13","author":"Lalatovi\u0107","year":"2023","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.heliyon.2025.e41629_bib175","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2217\/pgs-2018-0084","article-title":"Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin","volume":"19","author":"Liu","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib176","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2133\/dmpk.DMPK-12-RG-068","article-title":"Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans","volume":"28","author":"Oh","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib177","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bcpt.12943","article-title":"Gender-specific association between ABCC2 -24C>T SNP and reduction in triglycerides in Chilean patients treated with atorvastatin","volume":"122","author":"Prado","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib178","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/tpj.2011.59","article-title":"Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy","volume":"13","author":"Becker","year":"2013","journal-title":"Pharmacogenomics J."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib179","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3109\/00498254.2011.562566","article-title":"Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins","volume":"41","author":"Generaux","year":"2011","journal-title":"Xenobiotica"},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib180","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2217\/pgs-2023-0043","article-title":"The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing","volume":"24","author":"Alrajeh","year":"2023","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib181","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00228-021-03233-7","article-title":"Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study","volume":"78","author":"Mer\u0107ep","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib182","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s40001-023-01038-1","article-title":"Association between CYP3A4\/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?","volume":"28","author":"Maslub","year":"2023","journal-title":"Eur. J. Med. Res."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib183","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1592\/phco.31.10.942","article-title":"Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin","volume":"31","author":"Shin","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib184","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01213011-200506000-00007","article-title":"Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage","volume":"15","author":"Wilke","year":"2005","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2009.181","article-title":"UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo","volume":"87","author":"Riedmaier","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib186","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40291-013-0031-x","article-title":"UGT1A1\u221728 is associated with decreased systemic exposure of atorvastatin lactone","volume":"17","author":"Stormo","year":"2013","journal-title":"Mol. Diagn. Ther."},{"issue":"8","key":"10.1016\/j.heliyon.2025.e41629_bib187","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/FPC.0b013e3283544085","article-title":"The UGT1A3\u22172 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers","volume":"22","author":"Cho","year":"2012","journal-title":"Pharmacogenet Genomics"},{"issue":"17","key":"10.1016\/j.heliyon.2025.e41629_bib188","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib189","doi-asserted-by":"crossref","first-page":"519s","DOI":"10.1093\/advances\/nmy010","article-title":"Coenzyme Q10 as treatment for statin-associated muscle symptoms-A good idea, but","volume":"9","author":"Zaleski","year":"2018","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.heliyon.2025.e41629_bib190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Michalska-Kasiczak","year":"2015","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib191","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.heliyon.2025.e41629_bib192","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.atherosclerosis.2016.11.011","article-title":"Low vitamin D does not predict statin associated muscle symptoms but is associated with transient increases in muscle damage and pain","volume":"256","author":"Taylor","year":"2017","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib193","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bbagrm.2016.02.006","article-title":"Mechanisms of xenobiotic receptor activation: direct vs. indirect","volume":"1859","author":"Mackowiak","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib194","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40168-021-01050-9","article-title":"The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice","volume":"9","author":"Barretto","year":"2021","journal-title":"Microbiome"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib195","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/j.1476-5381.2011.01665.x","article-title":"Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor","volume":"165","author":"Hoffart","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib196","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd753","article-title":"PXR, CAR and drug metabolism","volume":"1","author":"Willson","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib197","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0026-895X(24)12603-X","article-title":"Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor","volume":"60","author":"Goodwin","year":"2001","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib198","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1124\/mol.105.013169","article-title":"Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha","volume":"68","author":"Ferguson","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib199","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1124\/dmd.31.11.1296","article-title":"Induction of ABCC3 (MRP3) by pregnane X receptor activators","volume":"31","author":"Teng","year":"2003","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib200","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/mol.64.2.316","article-title":"Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter","volume":"64","author":"Chen","year":"2003","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib201","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/mol.104.007161","volume":"67","author":"Sugatani","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib202","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.32.3.340","article-title":"Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression","volume":"32","author":"Gardner-Stephen","year":"2004","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib203","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1210\/me.2007-0002","article-title":"The xenobiotic-sensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-\/bile acid-sulfotransferase","volume":"21","author":"Echchgadda","year":"2007","journal-title":"Mol. Endocrinol."},{"issue":"22","key":"10.1016\/j.heliyon.2025.e41629_bib204","doi-asserted-by":"crossref","first-page":"9338","DOI":"10.1158\/0008-5472.CAN-08-0265","article-title":"Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer","volume":"68","author":"Meyer zu Schwabedissen","year":"2008","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib205","first-page":"1467","article-title":"Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor","volume":"29","author":"Staudinger","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib206","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s40262-020-00867-1","article-title":"Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies","volume":"59","author":"Elmeliegy","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib207","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1074\/jbc.M109326200","article-title":"Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor","volume":"277","author":"Kast","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib208","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1021\/mp0500824","article-title":"Activation of human CYP2C9 promoter and regulation by CAR and PXR in mouse liver","volume":"3","author":"Al-Dosari","year":"2006","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib209","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.heliyon.2025.e41629_bib210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.toxlet.2021.02.008","article-title":"Triptolide and atorvastatin synergistically promote hepatotoxicity in cultured hepatocytes and female Sprague-Dawley rats by inhibiting pregnane X receptor-mediated transcriptional activation of CYP3A4","volume":"342","author":"Zheng","year":"2021","journal-title":"Toxicol. Lett."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib211","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clpt.2005.04.007","article-title":"Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites","volume":"78","author":"Backman","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib212","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1067\/mcp.2000.111414","article-title":"Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations","volume":"68","author":"Kyrklund","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib213","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/sj.clpt.6100038","article-title":"Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers","volume":"81","author":"Lau","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib214","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0149-2918(08)80052-5","article-title":"Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study","volume":"30","author":"Zhang","year":"2008","journal-title":"Clin Ther"},{"issue":"38","key":"10.1016\/j.heliyon.2025.e41629_bib215","doi-asserted-by":"crossref","first-page":"23565","DOI":"10.1074\/jbc.272.38.23565","article-title":"Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR","volume":"272","author":"Choi","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib216","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.104.002741","article-title":"Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor","volume":"33","author":"Kobayashi","year":"2005","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib217","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1128\/MCB.19.9.6318","article-title":"Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene","volume":"19","author":"Kawamoto","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib218","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.106.010033","article-title":"Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes","volume":"34","author":"Jigorel","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib219","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.117.247296","article-title":"Establishing transcriptional signatures to differentiate PXR-, CAR-, and AhR-mediated regulation of drug metabolism and transport genes in cryopreserved human hepatocytes","volume":"365","author":"Moscovitz","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib220","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/mp9000298","article-title":"Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms","volume":"6","author":"Meyer zu Schwabedissen","year":"2009","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib221","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib222","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/nar\/gkac133","article-title":"Molecular basis of crosstalk in nuclear receptors: heterodimerization between PXR and CAR and the implication in gene regulation","volume":"50","author":"Bwayi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.heliyon.2025.e41629_bib223","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2022.104029","article-title":"Producing personalized statin treatment plans to optimize clinical outcomes using big data and machine learning","volume":"128","author":"Chi","year":"2022","journal-title":"J Biomed Inform"},{"issue":"9","key":"10.1016\/j.heliyon.2025.e41629_bib224","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1021\/acs.molpharmaceut.9b00458","article-title":"Transcriptional and post-transcriptional regulation of duodenal P-glycoprotein and MRP2 in healthy human subjects after chronic treatment with rifampin and carbamazepine","volume":"16","author":"Brueck","year":"2019","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib225","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib226","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/mol.104.005389","article-title":"Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor","volume":"67","author":"Fang","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib227","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.106.013243","article-title":"Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation","volume":"35","author":"Senekeo-Effenberger","year":"2007","journal-title":"Drug Metab. Dispos."},{"issue":"35","key":"10.1016\/j.heliyon.2025.e41629_bib228","doi-asserted-by":"crossref","first-page":"32852","DOI":"10.1074\/jbc.M305361200","article-title":"Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme","volume":"278","author":"Barbier","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2025.e41629_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2025.e41629_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115626","article-title":"Ligands and agonists of the aryl hydrocarbon receptor AhR: facts and myths","volume":"213","author":"Sl\u00e1dekov\u00e1","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib231","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bcp.2010.08.016","article-title":"A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP\/ABCG2 in LS174T cells","volume":"80","author":"Tompkins","year":"2010","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib232","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1515\/bc.2010.128","article-title":"An introduction to the molecular basics of aryl hydrocarbon receptor biology","volume":"391","author":"Abel","year":"2010","journal-title":"Biol. Chem."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib233","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21671","article-title":"Aryl-hydrocarbon receptor activation regulates constitutive androstane receptor levels in murine and human liver","volume":"46","author":"Patel","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.heliyon.2025.e41629_bib234","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/j.gastro.2010.03.033","article-title":"A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis","volume":"139","author":"Lee","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib235","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/bph.15789","article-title":"Aryl hydrocarbon receptor (AhR) activation contributes to high-fat diet-induced vascular dysfunction","volume":"179","author":"da Silva","year":"2022","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib236","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/hep.25571","article-title":"Aryl hydrocarbon receptor regulates the cholesterol biosynthetic pathway in a dioxin response element-independent manner","volume":"55","author":"Tanos","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib237","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.104.525774","article-title":"Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells","volume":"112","author":"Sen-Banerjee","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2025.e41629_bib238","article-title":"Kr\u00fcppel-like factor 15 in liver diseases: insights into metabolic reprogramming","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.heliyon.2025.e41629_bib239","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/dmd.123.001617","article-title":"KLF15-Cyp3a11 Axis regulates rifampicin-induced liver injury","volume":"52","author":"Hou","year":"2024","journal-title":"Drug Metab. Dispos."},{"issue":"4","key":"10.1016\/j.heliyon.2025.e41629_bib240","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/clpt.2009.2","article-title":"Pharmacoepigenetics: its role in interindividual differences in drug response","volume":"85","author":"Gomez","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"11","key":"10.1016\/j.heliyon.2025.e41629_bib241","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.biochi.2012.07.013","article-title":"DNA methylation dynamics in the hepatic CYP3A4 gene promoter","volume":"94","author":"Kacevska","year":"2012","journal-title":"Biochimie"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib242","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1124\/mol.108.052993","article-title":"Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation","volume":"75","author":"Li","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib243","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1124\/dmd.113.051201","article-title":"Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney","volume":"41","author":"Oda","year":"2013","journal-title":"Drug Metab. Dispos."},{"issue":"6","key":"10.1016\/j.heliyon.2025.e41629_bib244","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/jphp.12053","article-title":"Evidence for regulation of UDP-glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers","volume":"65","author":"Yasar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib245","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10010006","article-title":"Regulation of hepatic UGT2B15 by methylation in adults of asian descent","volume":"10","author":"Oeser","year":"2018","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib246","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1124\/dmd.117.076109","article-title":"Histone modifications regulate the developmental expression of human hepatic UDP-glucuronosyltransferase 1A1","volume":"45","author":"Nie","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"10","key":"10.1016\/j.heliyon.2025.e41629_bib247","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1111\/bcp.15376","article-title":"Effects of ABCB1 DNA methylation in donors on tacrolimus blood concentrations in recipients following liver transplantation","volume":"88","author":"Shi","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib248","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1124\/mol.108.052589","article-title":"Analysis of DNA methylation and histone modification profiles of liver-specific transporters","volume":"75","author":"Imai","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.heliyon.2025.e41629_bib249","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1038\/srep04283","article-title":"The effect of microRNAs in the regulation of human CYP3A4: a systematic study using a mathematical model","volume":"4","author":"Wei","year":"2014","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.heliyon.2025.e41629_bib250","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11811-y","article-title":"MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity","volume":"7","author":"Gill","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.heliyon.2025.e41629_bib251","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1124\/jpet.113.210658","article-title":"Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p","volume":"348","author":"Dluzen","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.heliyon.2025.e41629_bib252","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/hep4.1433","article-title":"Up-regulation of miR-let7a-5p leads to decreased expression of ABCC2 in obstructive cholestasis","volume":"3","author":"Balasubramaniyan","year":"2019","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.heliyon.2025.e41629_bib253","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844025000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:18:43Z","timestamp":1778887123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844025000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":251,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2405844025000088"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41629","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e41629"}}